Are Patients with Schizophrenia Reliably Reporting their Cannabis Use? An African Cross-sectional Study.

Q3 Psychology

Central nervous system agents in medicinal chemistry Pub Date : 2022-01-01 DOI:10.2174/1871524922666220620150033

Ismail Rammouz, Mohamed Merzouki, Sara Bouri, Aalouane Rachid, Amine Bout, Saïd Boujraf

{"title":"Are Patients with Schizophrenia Reliably Reporting their Cannabis Use? An African Cross-sectional Study.","authors":"Ismail Rammouz, Mohamed Merzouki, Sara Bouri, Aalouane Rachid, Amine Bout, Saïd Boujraf","doi":"10.2174/1871524922666220620150033","DOIUrl":null,"url":null,"abstract":"Background: Most studies of the prevalence of cannabis use among patients with schizophrenia used a self-report as declared by the patient himself. We hypothesize that patients with schizophrenia did not tell the truth and might underreport their use for many reasons to be discussed later. Indeed, the under-report of cannabis use among these patients can affect the effectiveness of their treatment.Aims: To assess the degree of agreement between the prevalence values obtained from patients' reports and the results of the toxicological tests.Methods: A cross-sectional study was carried out on 403 patients with schizophrenia. A sociodemographic, psychiatric history and illicit drug use profile was performed for each patient. We assessed the patients with the Positive and Negative Syndrome Scale (PANSS), Calgary Depression score (CDSS), Barratt Impulsiveness Score (BIS-10) and Medication Adherence Rating Scale (MARS). The consumption of cannabis used was confirmed with MINI International Neuropsychiatric Interview (MINI-DSM IV) and using toxicological analysis.Results: Among the 403 patients who consented to give their urine samples, 49.1% (198/403) tested positive for cannabis, and 41.41% (82/198) underreported their use. The sensitivity and specificity of the questionnaire were 0.58 and 0.74. Based on the comparison between sociodemographic and psychiatric history data of patients who self-report and underreport their cannabis use, no significant difference was observed except for the duration of cannabis use and the score on the medication adherence scale. Moreover, it was found that impulsivity, PANSS score, CDSS score, and the type of schizophrenia are not involved in predicting the underreporting of cannabis use.Conclusion: The rate of patients who under-report cannabis use is important. Therefore, toxicological analysis is becoming relevant for identifying drug use among schizophrenic patients and in the addictive comorbidity research field.","PeriodicalId":9799,"journal":{"name":"Central nervous system agents in medicinal chemistry","volume":"22 3","pages":"188-197"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Central nervous system agents in medicinal chemistry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1871524922666220620150033","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Psychology","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Most studies of the prevalence of cannabis use among patients with schizophrenia used a self-report as declared by the patient himself. We hypothesize that patients with schizophrenia did not tell the truth and might underreport their use for many reasons to be discussed later. Indeed, the under-report of cannabis use among these patients can affect the effectiveness of their treatment.

Aims: To assess the degree of agreement between the prevalence values obtained from patients' reports and the results of the toxicological tests.

Methods: A cross-sectional study was carried out on 403 patients with schizophrenia. A sociodemographic, psychiatric history and illicit drug use profile was performed for each patient. We assessed the patients with the Positive and Negative Syndrome Scale (PANSS), Calgary Depression score (CDSS), Barratt Impulsiveness Score (BIS-10) and Medication Adherence Rating Scale (MARS). The consumption of cannabis used was confirmed with MINI International Neuropsychiatric Interview (MINI-DSM IV) and using toxicological analysis.

Results: Among the 403 patients who consented to give their urine samples, 49.1% (198/403) tested positive for cannabis, and 41.41% (82/198) underreported their use. The sensitivity and specificity of the questionnaire were 0.58 and 0.74. Based on the comparison between sociodemographic and psychiatric history data of patients who self-report and underreport their cannabis use, no significant difference was observed except for the duration of cannabis use and the score on the medication adherence scale. Moreover, it was found that impulsivity, PANSS score, CDSS score, and the type of schizophrenia are not involved in predicting the underreporting of cannabis use.

Conclusion: The rate of patients who under-report cannabis use is important. Therefore, toxicological analysis is becoming relevant for identifying drug use among schizophrenic patients and in the addictive comorbidity research field.

查看原文本刊更多论文

精神分裂症患者报告大麻使用情况可靠吗?非洲横断面研究。

背景:大多数关于精神分裂症患者大麻使用流行率的研究使用患者自己声明的自我报告。我们假设精神分裂症患者没有说出真相，并且可能由于许多稍后讨论的原因而低估了他们的使用。事实上，这些患者使用大麻的情况报告不足可能会影响其治疗的有效性。目的:评估从患者报告中获得的患病率值与毒理学试验结果之间的一致程度。方法:对403例精神分裂症患者进行横断面研究。对每位患者进行了社会人口学、精神病史和非法药物使用概况调查。采用阳性和阴性症状量表(PANSS)、卡尔加里抑郁评分(CDSS)、Barratt冲动评分(BIS-10)和药物依从性评定量表(MARS)对患者进行评估。通过MINI国际神经精神病学访谈(MINI- dsm IV)和使用毒理学分析证实了使用大麻的消费。结果:在403名同意提供尿样的患者中，49.1%(198/403)的尿样检测为大麻阳性，41.41%(82/198)的尿样少报。问卷的敏感性和特异性分别为0.58和0.74。自我报告和少报大麻患者的社会人口学和精神病史数据比较，除大麻使用持续时间和药物依从性量表得分外，无显著差异。此外，还发现冲动性、PANSS评分、CDSS评分和精神分裂症类型与预测大麻使用漏报无关。结论:少报大麻使用的患者比例很重要。因此，毒理学分析在识别精神分裂症患者的药物使用和成瘾共病研究领域变得相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Central nervous system agents in medicinal chemistry Psychology-Neuropsychology and Physiological Psychology

CiteScore

2.10

自引率

0.00%

发文量

期刊介绍： Central Nervous System Agents in Medicinal Chemistry aims to cover all the latest and outstanding developments in medicinal chemistry and rational drug design for the discovery of new central nervous system agents. Containing a series of timely in-depth reviews written by leaders in the field covering a range of current topics, Central Nervous System Agents in Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments in the field.